Published by Josh White on 21st April 2026
(Sharecast News) - Crism Therapeutics reported positive preclinical results for its Docetaxel-ChemoSeed implant on Tuesday, highlighting improved efficacy and tolerability compared with standard chemotherapy in a prostate cancer model.
URL: http://www.digitallook.com/dl/news/story/35868721/...